Latest news for aTyr Pharma (NASDAQ:ATYR) Stock

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

WIIM

Nio shares are trading lower following a report suggesting the company plans to reduce car purchase incentives starting July 22.

TD Cowen analyst Helane Becker maintains Hawaiian Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HA#NASDAQ">HA</a>) with a Hold and raises the price target from $12 to $13.

News

Price Target

Analyst Ratings

TD Cowen Maintains Hold on Hawaiian Holdings, Raises Price Target to $13

B of A Securities analyst Sara Senatore maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Buy and lowers the price target from $83 to $79.

JACK

B of A Securities Maintains Buy on Jack In The Box, Lowers Price Target to $79

TD Cowen analyst Helane Becker maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Hold and lowers the price target from $60 to $39.

ALGT

TD Cowen Maintains Hold on Allegiant Travel, Lowers Price Target to $39

COIN

MARA

RIOT

Shares of crypto-linked stocks are trading lower amid a drop in the price of Bitcoin.

B of A Securities analyst Sara Senatore maintains Krispy Kreme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) with a Buy and lowers the price target from $19 to $16.

DNUT

B of A Securities Maintains Buy on Krispy Kreme, Lowers Price Target to $16

TD Cowen analyst Helane Becker maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Hold and lowers the price target from $6.5 to $4.

ULCC

TD Cowen Maintains Hold on Frontier Group Holdings, Lowers Price Target to $4

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is announcing its second-quarter earnings on Thursday. Wall Street expects $1.38 in EPS and $20 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=TSM"> before market hours</a>.
The stock is up 67.23% over the past year, +69.12% YTD.
Let&#8217;s look at what the charts indicate for Taiwan Semiconductor (aka TSMC) stock, and how the stock currently maps against Wall Street estimates.
<h1 class="wp-block-heading">TSMC Price Charts Bearish Ahead Of Q2 Earnings </h1>
Taiwan Semiconductor stock faces a moderately bearish trend with ongoing selling pressure, indicating potential future bearish movement.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="634" height="457" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113159/Screenshot-2024-07-17-at-8.32.42-PM.png" alt="" class="wp-image-441109" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113159/Screenshot-2024-07-17-at-8.32.42-PM.png 634w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113159/Screenshot-2024-07-17-at-8.32.42-PM-300x216.png 300w" sizes="(max-width: 634px) 100vw, 634px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The share price stands at $174.70, quite below the 8-day SMA of $185 and slightly below its 20-day SMA of $179.07, signaling a bearish trend. 
However, the stock is trading above its 50-day SMA of $165.66 and 200-day SMA of $127.10, all indicating bullish signals for medium to long-term prospects.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="634" height="457" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113210/Screenshot-2024-07-17-at-8.32.24-PM.png" alt="" class="wp-image-441110" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113210/Screenshot-2024-07-17-at-8.32.24-PM.png 634w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/17113210/Screenshot-2024-07-17-at-8.32.24-PM-300x216.png 300w" sizes="(max-width: 634px) 100vw, 634px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The MACD indicator is positive at 5.31, reinforcing a bullish outlook. The RSI is at 48.65 and treading downwards, suggesting the stock is likely heading towards oversold conditions.
The Bollinger Bands (25) ranges of $164.26-$191.12, with the stock trading in the upper bullish band, indicating bullish sentiment as well. Overall, while short-term indicators show bearish pressure, the longer-term technicals reflect strong bullish support for TSM.
Read Also: <a href="https://www.benzinga.com/government/24/07/39818236/nvidia-supplier-super-micro-computer-stock-is-down-wednesday-whats-going-on">Nvidia Supplier Super Micro Computer Stock Is Down Wednesday, What&#8217;s Going On?</a>
<h1 class="wp-block-heading">TSMC Analysts See 25% Upside</h1>
TSMC Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/TSM/analyst-ratings"> The consensus analyst rating</a> on Taiwan Semiconductor stock stands at an Overweight currently with a price target of $172.71. The three most recent analyst ratings for Taiwan Semiconductor Manufacturing Co Ltd were released by Needham, Susquehanna and Bernstein on July 15, July 11, and June 20, 2024, respectively. The average price target of $220 implies a 25.33% upside.
TSM Price Action: Taiwan Semiconductor&#8217;s stock was trading down 6.72% at $175.53 at the time of publication Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/24/07/39816230/whats-going-on-with-nvidia-amd-and-semiconductor-peer-stocks-on-wednesday">What&#8217;s Going On With Nvidia, AMD And More Semiconductor Stocks Wednesday?</a></li>
</ul>
Photo: Sundry Photography on Shutterstock

Analyst Color

Earnings

Technicals

Previews

Global

Tech

Trading Ideas

Taiwan Semiconductor Charts Show Mixed Signals As Q2 Earnings Loom: What To Expect

UUUU

Shares of US-traded uranium companies are trading lower amid a drop in the price of uranium.

TD Cowen analyst Helane Becker maintains Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) with a Buy and lowers the price target from $11 to $10.

VLRS

TD Cowen Maintains Buy on Controladora Vuela, Lowers Price Target to $10

B of A Securities analyst Sara Senatore maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Buy and lowers the price target from $29 to $24.

FWRG

B of A Securities Maintains Buy on First Watch Restaurant Gr, Lowers Price Target to $24

TD Cowen analyst Helane Becker maintains Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) with a Buy and lowers the price target from $61 to $59.

TD Cowen Maintains Buy on Delta Air Lines, Lowers Price Target to $59

B of A Securities analyst Sara Senatore maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Underperform and lowers the price target from $48 to $46.

CBRL

B of A Securities Maintains Underperform on Cracker Barrel Old, Lowers Price Target to $46

TD Cowen analyst Jason Seidl maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Hold and lowers the price target from $181 to $161.

JBHT

TD Cowen Maintains Hold on JB Hunt Transport Servs, Lowers Price Target to $161

B of A Securities analyst Katherine Griffin maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Underperform and raises the price target from $51 to $58.

B of A Securities Maintains Underperform on Brinker International, Raises Price Target to $58

AMBA

MKSI

MTSI

NXPI

RMBS

SMTC

Shares of chip stocks are trading lower amid reports Biden is considering further China restrictions. The sector may also be down following soft guidance from ASML.

B of A Securities analyst Julien Dumoulin-Smith maintains TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) with a Buy and raises the price target from $5 to $6.

TPIC

B of A Securities Maintains Buy on TPI Composites, Raises Price Target to $6

<a href="https://www.wsj.com/finance/banking/hsbc-names-group-cfo-georges-elhedery-as-group-chief-executive-1af662b6?mod=latest_headlines" title="https://www.wsj.com/finance/banking/hsbc-names-group-cfo-georges-elhedery-as-group-chief-executive-1af662b6?mod=latest_headlines">https://www.wsj.com/finance/banking/hsbc-names-group-cfo-georges-elhedery-as-group-chief-executive-1af662b6?mod=latest_headlines</a>

Management

HSBC

'HSBC Names Georges Elhedery As Chief Executive' - WSJ

Expanded access to the Caesars Sportsbook mobile platform brings a premier sports wagering experience to more sports fans on mobile and desktop
Just over three years after making history by opening the first sportsbook in a U.S. professional sports venue at Capital One Arena, Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) ("Caesars") announced today that its flagship mobile sports wagering platform, Caesars Sportsbook, is expanding its reach across Washington, D.C. Starting today, sports fans 21 and older can <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caesars.com%2Fsportsbook-and-casino%2Fdc%2Fget-the-app%2F&amp;esheet=54095428&amp;newsitemid=20240716582104&amp;lan=en-US&amp;anchor=download&amp;index=1&amp;md5=1b13a87140e0475c0abf773561544381">download</a> the Caesars Sportsbook app on iOS and Android, or access it via desktop, district-wide – <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsportsbook.caesars.com%2Fus%2Fdc%2Fbet%2Fpromos%2Fdc-faq&amp;esheet=54095428&amp;newsitemid=20240716582104&amp;lan=en-US&amp;anchor=except+on+federal+lands+and+designated+areas&amp;index=2&amp;md5=1aee5003d087c9b2046a9db1a9c2a9d0">except on federal lands and designated areas</a> surrounding other professional sports venues.

Caesars Sportsbook Expands Mobile Sports Betting Access In Washington, D.C.

Across the recent three months, 12 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $76.17, a high estimate of $100.00, and a low estimate of $46.00. A 6.77% drop is evident in the current average compared to the previous average price target of $81.70. 
<img src="https://www.benzinga.com/files/images/story/2024/1721235699_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Apellis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Apellis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Unraveling the Financial Story of Apellis Pharmaceuticals</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Apellis Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 284.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -38.55%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -28.8%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Apellis Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/atyr-stock-quote/">ATYR</a>) just reported results for the second quarter of 2023.<ul><li>aTyr Pharma reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -28 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/atyr-stock-earnings-atyr-pharma-for-q2-of-2023/">ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

aTyr Pharma

News

Latest news for aTyr Pharma (NASDAQ:ATYR) Stock

People Also Watch